Takeda Loses Patent Fight Over Roche's Hemlibra Drug
By Andrew Karpan (January 14, 2022, 4:11 PM EST) -- A federal court in Delaware has said that a Takeda Pharmaceutical Co. Ltd. unit's patent covering antibodies isn't valid after all, sinking the Japanese multinational's infringement case against the Roche-owned company that makes the blockbuster hemophilia drug Hemlibra.
U.S. Circuit Judge Timothy B. Dyk — who has been overseeing the infringement lawsuit in a federal courthouse in Wilmington since 2018 — ruled Thursday that claims in a patent owned by Takeda's Baxalta Inc. were "invalid for lack of enablement," almost five years after Baxalta sued Roche's Genentech Inc. over infringing the patent in 2017.
Judge Dyk's office is expected to unseal an...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!